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Blood pressure variability in individuals with and
without (pre)diabetes:TheMaastricht Study
Tan Lai Zhoua,b, Abraham A. Kroona,b, Koen D. Reesinkb,c, Miranda T. Schrama,b,d
Annemarie Kostere,f, Nicolaas C. Schapera,b,f, Pieter C. Dagnelieb,f,g, Carla J.H. van der Kallena,b,
Simone J.S. Sepa,b, Coen D.A. Stehouwera,b, and Ronald M.A. Henrya,b,d
Objective: The mechanisms associating (pre)diabetes and
cardiovascular disease (CVD) are incompletely understood.
We hypothesize that greater blood pressure variability
(BPV) may underlie this association, due to its association
with (incident) CVD. Therefore, we investigated the
association between (pre)diabetes and very short-term to
mid-term BPV, that is within-visit, 24-h and 7-day BPV.
Methods: Cross-sectional data from The Maastricht Study
[normal glucose metabolism (NGM), n¼1924; prediabetes,
n¼511; type 2 diabetes mellitus (T2DM), n¼ 975; 51%
men, aged 608 years]. We determined SD for within-
visit BPV (n¼3244), average real variability for 24-h BPV
(n¼ 2699) day (0900–2100 h) and night (0100–0600 h)
separately, and SD for 7-day BPV (n¼2259). Differences in
BPV as compared with NGM were assessed by multiple
linear regressions with adjustment for potential
confounders.
Results: In T2DM, the average systolic/diastolic values of
within-visit, 24-h and 7-day BPV were 4.8/2.6, 10.5/7.3
and 10.4/6.5 mmHg, respectively, and in prediabetes 4.9/
2.6, 10.3/7.0 and 9.4/5.9 mmHg, respectively. T2DM was
associated with greater nocturnal systolic BPV [0.42 mmHg
(95% confidence interval: 0.05–0.80)], and greater 7-day
systolic [0.76 mmHg (0.32–1.19)] and diastolic BPV
[0.65 mmHg (0.29–1.01)], whereas prediabetes was
associated with greater within-visit systolic BPV only
[0.35 mmHg (0.06–0.65)], as compared with NGM.
Conclusion: Both T2DM and prediabetes are associated
with slightly greater very short-term to mid-term BPV,
which may, according to previous literature, explain a small
part of the increased CVD risk seen in (pre)diabetes.
Nevertheless, these findings do not detract from the fact
that very short-term to mid-term BPV is substantial and
important in individuals with and without (pre)diabetes.
Keywords: average real variability, blood pressure
variability, cardiovascular diseases, diabetes mellitus,
prediabetic state
Abbreviations: BPV, blood pressure variability; CKD-EPI,
Chronic Kidney Disease Epidemiology Collaboration; eGFR,
estimated glomerular filtration rate; HDL-C, HDL
cholesterol; LDL-C, LDL cholesterol; NGM, normal glucose
metabolism; T2DM, type 2 diabetes mellitus
INTRODUCTION
T
he mechanisms underlying the associations be-
tween type 2 diabetes (T2DM) and cardiovascular
disease (CVD) are still only partially understood [1].
Importantly, the pathways linking T2DM to CVD are
thought to be already present, to a somewhat lesser extent,
in prediabetes [2]. A better understanding of these mecha-
nisms is crucial, as it has been projected that, in 2025, 600
million individuals will suffer from T2DM, which will be
followed by an epidemic of CVD [3].
Blood pressure (BP) variability (BPV), that is greater
fluctuations of SBP or DBP at given mean pressures, has
been shown tobeassociatedwith incidentCVD independent
of mean pressures [4] and thus may play a role in the
association between (pre)diabetes and CVD. However,
BPV in individuals with (pre)diabetes has not been system-
atically investigated, as previous studies have been relatively
small [5–7], have targeted selected study populations [8,9],
have used nonstandardized BP measurements [8,9] and/or
have not adequately adjusted for the use of the various
classes of antihypertensive medication [5–9], which may
increase or decrease BPV depending on their therapeutic
mechanism of action [10,11]. In addition, BPV in individuals
with (pre)diabetes has not been systematically compared
with that in individuals with normal glucose metabolism
(NGM). The latter is important, because BP regulation in
individuals with (pre)diabetes is known to differ from that in
individuals with NGM in many ways [12], and these differ-
encesmay increaseBPV [13]. We therefore hypothesized that
BPV may be greater in individuals with (pre)diabetes. In-
deed, there is some evidence that this may be the case [5–9].
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In view of the above, we investigated very short-term to
mid-term (i.e. within-visit, 24-h and 7-day) BPV in partic-
ipants of The Maastricht Study, a large population-based
cohort study in which individuals with T2DM have been
oversampled [14].
METHODS
Study design and population
We used data from The Maastricht Study, an observational
prospective population-based cohort study. The rationale
and methodology have been described previously [14]. In
brief, the study focuses on the cause, pathophysiology,
complications and comorbidities of T2DM and is character-
ized by an extensive phenotyping approach. Eligible for
participation were all individuals aged between 40 and 75
years and living in the southern part of the Netherlands.
Participants were recruited through mass media campaigns
and from the municipal registries and the regional Diabetes
Patient Registry via mailings. Recruitment was stratified
according to known T2DM status, with an oversampling
of individuals with T2DM, for reasons of efficiency. The
current report includes cross-sectional data from the first
3451 participants, who completed the baseline survey
between November 2010 and September 2013. The exami-
nations of each participant were performed within a time
window of 3 months. The study has been approved by the
institutional medical ethical committee (NL31329.068.10)
and the Minister of Health, Welfare and Sports of the
Netherlands (Permit 131088-105234-PG). All participants
gave written informed consent.
Data collection
Blood pressure measurements and determination of
blood pressure variability
Within-visit BPV was derived from office BP measurements
according to international standards [15]. In short, office BP
measurements were performed with the use of an oscillo-
metric device (705-IT; Omron Healthcare, Kyoto, Japan), in a
seated position on the right arm by trained research assis-
tants, after 10min of rest. BP was measured three times
consecutively, with a 1-min interval. BP readings were taken
between 09:30 and 11:30 a.m. as part of the first investiga-
tional study visit [14]. Within-visit BPV was computed as the
SD when at least two BP readings were available.
Twenty-four-hour BPV was derived from ambulatory BP
measurements according to international standards [16]. In
short, ambulatory BP measurements were performed with
the use of an oscillometric device (WatchBP O3; Microlife,
Widnau, Switzerland) on the nondominant arm. Between
0800 and 2300 h readings were taken every 15 min; be-
tween 2300 and 0800 h, the interval was set at 30min.
Average real variability was calculated as measurement
of 24-h BPV. The average real variability is the sum of
the absolute differences of consecutive BP measurements
divided by the number of differences and therefore takes
into account the time series variability [17]. The 24-h BPV
was calculated when at least 14 valid BP differences during
daytime and at least seven valid BP differences during
night-time were available. In addition, day (between
0900 and 2100 h) and night (between 0100 and 0600 h)
average real variability values were analyzed separately.
Seven-day BPV was derived from home BP measure-
ments according to international standards [18]. In short,
home BP measurements were performed by participants
with the use of an oscillometric device (WatchBP Home;
Microlife) for 7 consecutive days, after instruction by
trained researchers. Participants were instructed to measure
their BP after at least 5-min rest in a seated position in the
morning before breakfast and in the evening after dinner on
the nondominant arm. The device measured BP twice
consecutively each reading, with a 1-min interval. As 7-
day BPV variable, SD was computed when at least 15 BP
readings were available.
Glucose metabolism status
To determine glucose metabolism status, all participants,
except those who used insulin, underwent a standardized
2-h 75g oral glucose tolerance test (OGTT) after an overnight
fast. For safety reasons,participantswith a fastingglucose level
above 11.0mmol/l, as determined by a finger prick, did not
undergo theOGTT. For these individuals, fastingglucose level
and information about diabetes medication were used to
determine glucose metabolism status. Glucose metabolism
status was defined according to the WHO 2006 criteria into
NGM, prediabetes (impaired fasting glucose and/or impaired
glucose tolerance) and T2DM [19]. Participants with type 1
diabetes or other forms of diabetes were excluded.
Covariates
Alcohol consumption, smoking status, history of CVD and
physical activity were assessed by questionnaire. Alcohol
consumption was defined as nonconsumer, low consumer
(7 alcoholic drinks/week for women; 14 alcoholic
drinks/week for men) or high consumer (>7 alcoholic
drinks/week for women; >14 alcohol drinks/week for
men). Smoking status was categorized into never, former
and current smoker. BMI, waist circumference, total cho-
lesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol
(LDL-C), triglycerides, fasting plasma glucose, postload
glucose and glycosylated hemoglobin (HbA1c) were deter-
mined as described elsewhere [14]. Estimated glomerular
filtration rate (eGFR) was computed with the Chronic
Kidney Disease Epidemiology Collaboration formula, using
serum creatinine and cystatin C [20]. Information on the use
of lipid-modifying and/or antihypertensive medication, that
is generic names, doses and frequencies, were collected
during an in person medication interview.
Statistical analysis
All data were analyzed using IBM SPSS software version
23.0 for Windows (IBM Corp., Somers, New York, USA).
Data are presented as n (%), mean SD or median [inter-
quartile range (IQR)]. To test for baseline differences, one-
way analysis of variance (with P for linear trend) or the
Kruskal–Wallis test for normally and nonnormally distrib-
uted continuous variables respectively, and x2 test for
categorical variables were used. Associations between pre-
diabetes, T2DM and BPV (within-visit, 24-h and 7-day;
systolic and diastolic) were examined with the use of
multiple linear regression models. Model 1 was adjusted
Zhou et al.
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for age and sex; model 2 was additionally adjusted for mean
SBP or DBP (either from office, 24-h or 7-day BP measure-
ments, as appropriate); model 3 was additionally adjusted
for smoking status and alcohol consumption; model 4 was
additionally adjusted for BMI, history of CVD, HDL-C, LDL-C,
use of lipid-modifying medication, eGFR; and model 5 was
additionally adjusted for antihypertensive medication classes
(beta-blockers, angiotensin-converting-enzyme inhibitors,
angiotensin II receptor blockers, calcium channel blockers
andnonloop diuretics separately). Thesemodels were repeat-
ed in a series of additional analyses for within-visit BPV with
coefficient of variation and maximum–minimum difference
instead of SD, for 24-h BPV with weighted SD and weighted
coefficient of variation [21] instead of average real variability,
and for 7-day BPV with coefficient of variation and average
real variability instead of SD. Further additional analyses were
done with adjustments for waist circumference (instead of
BMI), heart rate (HR), the actual number of BP measurements
and physical activity as confounders. In addition, to test
whether these associations were modified by sex, we used
interaction terms between glucose metabolism status and sex
in the fully adjusted models. A two-sided P value of less than
0.05 was considered statistically significant [22], except for the
interaction analyses, in which we used P less than 0.10.
RESULTS
Study population
From the 3451 participants, 41 participants with type 1
diabetes or other forms of diabetes were excluded. Data
on covariates were missing for three participants on BMI,
for four participants on cholesterol values, for four on
medication history, for 33 on eGFR, for 63 on smoking
habits, for 69 on alcohol use and for 108 on history of prior
CVD (not mutually exclusive). In addition, data on BPs
were missing for four participants on office BP, for 363
participants on 24-h BP and for 976 participants on 7-day
home BP (not mutually exclusive). In the remaining par-
ticipants, 3244 participants had adequate office BP mea-
surement data, 2699 participants had adequate 24-h
ambulatory BP measurement data and 2259 participants
had adequate 7-day home BP measurement data [not mu-
tually inclusive (Fig. 1)]. Missing data on BP measurements
were due to logistic and technical reasons (e.g. measure-
ment failures). Participants with and without missing data
did not differ with regard to their baseline clinical character-
istics, except for smoking [participants with missing ambu-
latory BP measurement data were more often current
smokers (18.0 vs. 13.0%)].
FIGURE 1 Flow diagram delineating the derivation of the final study population. ABPM, ambulatory blood pressure measurement; BPV, blood pressure variability; CVD,
cardiovascular disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration; HBPM, home blood pressure measurement; OBP, office blood pressure; T1DM, type 1
diabetes mellitus.
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Characteristics of the study population
Tables 1 and 2 show characteristics of the within-visit BPV
study population categorized according to glucose metabo-
lism status. FromNGMtoT2DM, age, BMI, HbA1c, prior CVD
and the use of lipid-modifying medication increased (P for
trend<0.001); TC and LDL-C decreased (P for trend<0.001).
The use of antihypertensive medication increased (P for
trend <0.001), as did values of systolic, ambulatory and
home BP measurements (P for trend<0.001). All calculated
BPV variables, except for within-visit systolic BPV, increased
from NGM to T2DM (P for trend <0.001–0.069). The char-
acteristics of the within-visit, 24-h and 7-day BPV study
populations were similar (Supplemental material Tables S1
and S2, http://links.lww.com/HJH/A838).
Associations between glucose metabolism
status and blood pressure variability
Within-visit blood pressure variability
After adjustment for age, sex (model 1), mean SBP or
DBP (model 2), smoking behavior and alcohol consump-
tion (model 3), BMI, prior CVD, HDL-C, LDL-C, lipid-
modifying medication, eGFR (model 4) and antihyperten-
sive medication (model 5), only prediabetes was
associated with statistically significantly greater within-
visit systolic BPV as compared with NGM [regression
coefficient (b) and 95% confidence interval]: 0.35 mmHg
(0.06–0.65), whereas T2DM was not (Table 3, upper
panel).
TABLE 1. Characteristics of the within-visit blood pressure variability study population
NGM, n¼1838 Prediabetes, n¼496 T2DM, n¼908 P (trend)a
Age (years) 57.98.2 61.57.5 62.77.7 <0.001
Men 797 (43.3%) 270 (54.4%) 620 (68.3%) <0.001
Smoking behavior <0.001
Never 719 (39.1%) 148 (29.8%) 257 (28.3%)
Former 887 (48.2%) 286 (57.7%) 507 (55.8%)
Current 233 (12.7%) 62 (12.5%) 144 (15.9%)
Alcohol consumption <0.001
None 249 (13.5%) 79 (15.9%) 275 (30.3%)
Low 1073 (58.3%) 262 (52.8%) 457 (50.3%)
High 517 (28.1%) 156 (31.3%) 176 (19.4%)
History of cardiovascular disease 219 (11.9%) 69 (13.9%) 256 (28.2%) <0.001
BMI (kg/m2) 25.53.6 27.84.2 29.85.0 <0.001
Waist circumference (cm) 90.511.2 98.312.4 105.813.5 <0.001
MVPA (h/week)b 6.24.5 5.14.1 4.34.0 <0.001
Total cholesterol (mmol/l) 5.61.0 5.41.1 4.41.0 <0.001
HDL cholesterol (mmol/l) 1.70.5 1.50.4 1.30.4 <0.001
LDL cholesterol (mmol/l) 3.40.9 3.31.0 2.40.9 <0.001
Triglycerides (mmol/l) 1.06 (0.80–1.45) 1.35 (1.02–1.83) 1.53 (1.12–2.14) <0.001
eGFR (ml/min per 1.73 m2) 90.313.2 86.714.1 84.717.1 <0.001
HbA1c (mmol/mol)c 36.03.7 38.84.5 52.111.6 <0.001
Fasting plasma glucose (mmol/l)d 5.20.4 5.90.6 7.92.0 <0.001
Postload glucose (mmol/l)e 5.41.1 8.11.7 14.33.8 <0.001
Use of antidiabetic medication – – 711 (78.3%)
Oral antidiabetics – – 663 (73.0%)
Insulin – – 194 (21.4%)
Use of lipid-modifying medication 303 (16.5%) 175 (35.3%) 679 (74.8%) <0.001
Use of antihypertensive medication 408 (22.2%) 224 (45.2%) 654 (72.0%) <0.001
Beta-blockers 165 (9.0%) 105 (21.2%) 308 (33.9%) <0.001
Calcium channel blockers 66 (3.6%) 38 (7.7%) 192 (21.1%) <0.001
ACE inhibitors 101 (5.5%) 46 (9.3%) 238 (26.2%) <0.001
Angiotensin II receptor blockers 177 (9.6%) 111 (22.4%) 301 (33.1%) <0.001
Diuretics 125 (6.8%) 94 (19.0%) 305 (33.6%) <0.001
Blood pressure measurements
Mean office SBP (mmHg) 130.717.2 137.517.0 142.318.1 <0.001
Mean office DBP (mmHg) 75.29.9 78.19.6 77.39.7 <0.001
Mean 24-h SBP (mmHg)f 118.711.2 122.511.9 123.612.2 <0.001
Mean 24-h DBP (mmHg)f 75.37.2 76.27.1 74.37.2 0.010
Mean home SBP (mmHg)g 124.012.8 128.712.3 133.513.4 <0.001
Mean home DBP (mmHg)g 77.08.5 78.07.7 77.87.9 0.029
Data are presented as n (%), mean SD or median (IQR). eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; MVPA, moderate-to-vigorous physical activity;
NGM, normal glucose metabolism; T2DM, type 2 diabetes mellitus.
aP (Trend) for comparing linear trends across participants with normal glucose metabolism, prediabetes and T2DM were calculated with one-way ANOVA for normally distributed
variables, the Kruskal–Wallis test for nonnormally disturbed variables and the x2 test for categorical variables.
bAvailable in 2834 participants (n¼1647 for NGM, n¼439 for prediabetes, n¼748 for T2DM).
cAvailable in 3231 participants (n¼1933 for NGM, n¼439 for prediabetes, n¼905 for T2DM).
dAvailable in 3241 participants (n¼1838 for NGM, n¼496 for prediabetes, n¼907 for T2DM).
eAvailable in 3011 participants (n¼ 1834 for NGM, n¼ 494 for prediabetes, n¼ 683 for T2DM).
fValues shown for 24-h BPV study population (n¼1535 for NGM, n¼411 for prediabetes, n¼753 for T2DM).
gValues shown for 7-day BPV study population (n¼1270 for NGM, n¼337 for prediabetes, n¼652 for T2DM).
Zhou et al.
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TABLE 3. Associations between glucose metabolism status and within-visit, 24-h and 7-day blood pressure variability
NGM (ref) Prediabetes T2DM
b (95% CI) b (95% CI) b (95% CI)
Within-visit BPV
SDSBP (mmHg)
Model 1 – 0.37 (0.08–0.66) 0.26 (0.01–0.50)
Model 2 – 0.26 (0.03 to 0.54) 0.05 (0.20 to 0.29)
Model 3 – 0.26 (0.03 to 0.55) 0.04 (0.21 to 0.28)
Model 4 – 0.36 (0.07–0.66) 0.23 (0.07 to 0.53)
Model 5 – 0.35 (0.06–0.65) 0.26 (0.04 to 0.56)
SDDBP (mmHg)
Model 1 – 0.09 (0.09 to 0.26) 0.10 (0.05 to 0.26)
Model 2 – 0.04 (0.14 to 0.21) 0.07 (0.07 to 0.21)
Model 3 – 0.04 (0.14 to 0.21) 0.04 (0.09 to 0.20)
Model 4 – 0.07 (0.11 to 0.25) 0.14 (0.04 to 0.32)
Model 5 – 0.05 (0.13 to 0.23) 0.10 (0.08 to 0.28)
24-h BPV
ARVSBP (mmHg)
Model 1 – 0.42 (0.15–0.68) 0.68 (0.46–0.90)
Model 2 – 0.24 (0.01 to 0.49) 0.54 (0.33–0.75)
Model 3 – 0.23 (0.02 to 0.48) 0.50 (0.28–0.71)
Model 4 – 0.03 (0.22 to 0.28) 0.15 (0.10 to 0.40)
Model 5 – 0.02 (0.23 to 0.28) 0.14 (0.11 to 0.39)
ARVDBP (mmHg)
Model 1 – 0.12 (0.08 to 0.32) 0.36 (0.19–0.53)
Model 2 – 0.07 (0.13 to 0.27) 0.42 (0.25–0.58)
Model 3 – 0.07 (0.13 to 0.26) 0.38 (0.21–0.55)
Model 4 – 0.09 (0.29 to 0.11) 0.07 (0.13 to 0.27)
Model 5 – 0.10 (0.30 to 0.10) 0.06 (0.15 to 0.26)
7-day home BPV
SDSBP (mmHg)
Model 1 – 0.41 (0.05 to 0.87) 1.42 (1.04–1.80)
Model 2 – 0.08 (0.35 to 0.51) 0.68 (0.32–1.04)
Model 3 – 0.06 (0.37 to 0.49) 0.69 (0.32–1.06)
Model 4 – 0.13 (0.31 to 0.57) 0.79 (0.35–1.22)
Model 5 – 0.06 (0.37 to 0.50) 0.76 (0.32–1.19)
SDDBP (mmHg)
Model 1 – 0.29 (0.08 to 0.66) 0.87 (0.57–1.17)
Model 2 – 0.19 (0.16 to 0.55) 0.84 (0.55–1.13)
Model 3 – 0.18 (0.18 to 0.54) 0.83 (0.53–1.13)
Model 4 – 0.17 (0.19 to 0.53) 0.69 (0.33–1.04)
Model 5 – 0.12 (0.24 to 0.48) 0.65 (0.29–1.01)
Multiple linear regression analyses comparing differences in within-visit, 24-h and 7-day BPV between individuals with (pre)diabetes and normal glucose metabolism. Model 1 adjusted
for age and sex; model 2 additionally adjusted for mean SBP or DBP (where appropriate); model 3: additionally adjusted for alcohol abuse and smoking behavior; model 4: additionally
adjusted for BMI, prior CVD, HDL, LDL, lipid-lowering medication and eGFR; model 5: additionally adjusted for classes of antihypertensive medication. Bold values denote statistically
significant associations. There were 3244 individuals (1535 with NGM, 496 with prediabetes, 908 with T2DM) included in the analyses between within-visit BPV and (pre)diabetes, 2699
individuals (1535 with NGM, 411 with prediabetes, 753 with T2DM) included in the analyses between 24-h BPV and (pre)diabetes, 2259 individuals (1270 with NGM, 337 with
prediabetes, 625 with T2DM) included in the analyses between 7-day BPV and (pre)diabetes. ARV, average real variability; CI, confidence interval; NGM, normal glucose metabolism;
T2DM, type 2 diabetes mellitus.
TABLE 2. Within-visit, 24-h and 7-day blood pressure variability according to glucose metabolism status
NGM, n¼1839 Prediabetes, n¼496 T2DM, n¼908 P (trend)a
Within-visit BPV
SDSBP (mmHg) 4.482.76 4.932.98 4.823.08 0.001
SDDBP (mmHg) 2.461.62 2.591.73 2.621.93 0.013
24-h BPV (n¼1535) (n¼411) (n¼753)
ARVSBP (mmHg) 9.732.37 10.272.58 10.502.51 <0.001
Day (0900–2100 h) 10.293.25 10.623.33 10.663.23 0.008
Night (0100–0600 h) 8.843.34 9.403.29 10.203.76 <0.001
ARVDBP (mmHg) 6.851.72 7.021.80 7.252.01 <0.001
Day (0900–2100 h) 7.132.61 7.232.72 7.342.79 0.069
Night (0100–0600 h) 6.462.63 6.782.91 7.133.13 <0.001
7-day home BPV (n¼1270) (n¼337) (n¼652)
SDSBP (mmHg) 8.763.57 9.373.40 10.434.39 <0.001
SDDBP (mmHg) 5.552.78 5.892.47 6.493.67 <0.001
Data are presented as mean SD. ANOVA, analysis of variance; ARV, average real variability; NGM, normal glucose metabolism; T2DM, type 2 diabetes mellitus.
aP (trend) for comparing linear trends across participants with normal glucose metabolism, prediabetes and T2DM were calculated with one-way ANOVA.
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Both prediabetes and T2DM were not statistically signif-
icantly associated with within-visit diastolic BPV as com-
pared with NGM (Table 3, upper panel).
Twenty-four-hour blood pressure variability
After adjustment for the covariates of the models 1–3,
T2DM, but not prediabetes, was associated with greater
24-h systolic BPV as compared with NGM [0.50 mmHg
(0.28–0.71)]. These results were attenuated and not statisti-
cally significant after further adjustment for the covariates of
model 4 [0.15 mmHg (0.13 to 0.27)] or model 5
[0.14 mmHg (0.11 to 0.39)] (Table 3, middle panel). The
attenuating effect seen between models 3 and 4 was mainly
caused by adding BMI in model 4.
After adjustment for the covariates of the models 1–3,
only T2DM, but not prediabetes, was associated with great-
er 24-h diastolic BPV as compared with NGM [0.38 mmHg
(0.21–0.55)]. These results were attenuated and not statisti-
cally significant after further adjustment for the covariates of
model 4 [0.07 mmHg (0.13 to 0.27)] or model 5
[0.06 mmHg (0.15 to 0.26)] (Table 3, middle panel). Again,
the attenuating effect seen between models 3 and 4 was
mainly caused by adding BMI in model 4.
If we analyzed daytime and night-time BPV separately,
only T2DM was associated with greater nocturnal
systolic BPV after adjustment for the covariates of the
models 1–5 as compared with NGM [0.42 mmHg (0.05–
0.80)] (Table 4).
Seven-day blood pressure variability
After adjustment for the covariates of the models 1–3, only
T2DM, but not prediabetes, was associated with greater
7-day systolic BPV as compared with NGM [0.69 mmHg
(0.32–1.06)]. This association became somewhat stronger
after further adjustment for the covariates of model 4
[0.79 mmHg (0.35–1.22)] and model 5 [0.76 mmHg (0.32–
1.19)].
After adjustment for the covariates of the models
1–3, only T2DM, but not prediabetes, was associated with
greater 7-day diastolic BPV as compared with NGM
[0.83 mmHg (0.53–1.13)]. This association was somewhat
attenuated after further adjustment for the covariates of
model 5 [0.65 mmHg (0.29–1.01)].
Additional analyses
After additional adjustment for waist circumference (instead
of BMI), HR, the actual number of BP measurements and
physical activity, the results did not materially change
(Supplemental material Tables S3–S6, http://links.lww.
com/HJH/A838).
If we repeated the analyses for within-visit BPV with
coefficient of variation and the difference between maxi-
mum and minimum BP, and for 24-h BPV with weighted SD
and weighted coefficient of variation, and for 7-day BPV
with average real variability and coefficient of variation, the
results were not materially changed (Supplemental material
Tables S7–S9, http://links.lww.com/HJH/A838).
TABLE 4. Associations between glucose metabolism status and blood pressure variability during daytime and night-time as estimated
from ambulatory blood pressure measurements
NGM (ref) Prediabetes T2DM
b (95% CI) b (95% CI) b (95% CI)
24-h BPV, day only
ARVSBP (mmHg)
Model 1 – 0.28 (0.07 to 0.63) 0.44 (0.15–0.73)
Model 2 – 0.12 (0.22 to 0.45) 0.36 (0.08–0.64)
Model 3 – 0.10 (0.24 to 0.44) 0.29 (0.01–0.58)
Model 4 – 0.10 (0.44 to 0.24) 0.08 (0.42 to 0.26)
Model 5 – 0.09 (0.43 to 0.25) 0.06 (0.41 to 0.29)
ARVDBP (mmHg)
Model 1 – 0.12 (0.17 to 0.42) 0.28 (0.04–0.53)
Model 2 – 0.06 (0.23 to 0.35) 0.39 (0.14–0.63)
Model 3 – 0.05 (0.24 to 0.34) 0.32 (0.07–0.57)
Model 4 – 0.14 (0.43 to 0.16) 0.04 (0.34 to 0.25)
Model 5 – 0.13 (0.43 to 0.16) 0.06 (0.36 to 0.24)
24-h BPV, night only
ARVSBP (mmHg)
Model 1 – 0.36 (0.01 to 0.73) 1.07 (0.76–1.38)
Model 2 – 0.27 (0.10 to 0.64) 0.82 (0.51–1.13)
Model 3 – 0.27 (0.10 to 0.64) 0.85 (0.54–1.17)
Model 4 – 0.01 (0.36 to 0.38) 0.42 (0.04–0.79)
Model 5 – 0.01 (0.38 to 0.36) 0.42 (0.05–0.80)
ARVDBP (mmHg)
Model 1 – 0.20 (0.11 to 0.50) 0.44 (0.18–0.69)
Model 2 – 0.15 (0.16 to 0.45) 0.42 (0.16–0.67)
Model 3 – 0.14 (0.17 to 0.44) 0.40 (0.14–0.66)
Model 4 – 0.07 (0.38 to 0.24) 0.03 (0.34 to 0.28)
Model 5 – 0.09 (0.41 to 0.22) 0.07 (0.38 to 0.25)
Multiple linear regression analyses comparing differences in daytime and night-time BPV between individuals with (pre)diabetes and normal glucose metabolism. Model 1: adjusted for
age and sex; model 2: additionally adjusted for mean SBP or DBP (where appropriate); model 3: additionally adjusted for alcohol abuse and smoking behavior; model 4: additionally
adjusted for BMI, prior CVD, HDL, LDL, lipid-lowering medication and eGFR; and model 5: additionally adjusted for classes of antihypertensive medication. Bold values denote statistically
significant associations. There were 2766 individuals (1563 with NGM, 426 with prediabetes, 777 with T2DM) included in the analyses between day BPV and (pre)diabetes, 2790
individuals (1586 with NGM, 424 with prediabetes, 780 with T2DM) included in the analyses between nocturnal BPV and (pre)diabetes. ARV, average real variability; CI, confidence
interval; NGM, normal glucose metabolism; T2DM, type 2 diabetes mellitus.
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Sex was an effect modifier in some of the associations
between glucose metabolism status and BPV, but not all:
the associations between prediabetes, and systolic within-
visit and 7-day BPV were weaker in women, whereas the
associations between prediabetes and T2DM, and systolic
24-h BPV were stronger in women. For both day and night,
the association between T2DM and systolic BPV was stron-
ger in women (details presented in Supplemental material
Table S10, http://links.lww.com/HJH/A838).
Further analyses into antihypertensive medication and
class effects on BPV [10] were hampered by a severe loss of
statistical power (data not shown).
DISCUSSION
The current study had two main findings. First, the average
systolic/diastolic values of within-visit, 24-h and 7-day BPV
in our study population were substantial: 4.8/2.6, 10.5/7.3
and 10.4/6.5 mmHg, respectively, in individuals with
T2DM, and 5.0/2.6, 10.3/7.0 and 9.4/5.9 mmHg, respective-
ly, in individuals with prediabetes. Second, these values
were, after adjustment for potential confounders, slightly
larger than those in individuals with NGM. Specifically,
T2DM was associated with significantly greater nocturnal
systolic BPV and greater 7-day systolic and diastolic BPV,
whereas prediabetes was associated with significantly
greater within-visit systolic BPV only. According to previous
literature, the slightly greater very short-term to mid-term
BPV seen in (pre)diabetes corresponds to a relatively
modest 4% increased risk of cardiovascular events over
an observation period of 5–7 years (e.g. an increase from
9.0 to 9.4%) [23,24], on the assumption that there is no
interaction (synergy) between (pre)diabetes and very
short-term to mid-term BPV. However, the average very
short-term to mid-term BPV values we observed are in
agreement with previous studies, which have shown that
very short-term to mid-term BPV plays an important role in
incident CVD [4,23,24]. Thus, these findings suggest that
very short-term to mid-term BPV may, at most, explain a
small part of the increased CVD risk seen in (pre)diabetes,
but it does not detract from the fact that, regardless of the
presence of (pre)diabetes, very short-term to mid-term BPV
is substantial and important.
Previous studies on BPV in (pre)diabetes have not yielded
consistent results. Two large Asian population-based studies
did notpresent numerical values of differences inBPVvalues
between individuals with (pre)diabetes and NGM [8,9], and
one study [8] investigated associations with new-onset dia-
betes only. In addition, two relatively small studies [5,6]
showed large differences in BPV, up to 3.7mmHg, between
individuals with (pre)diabetes and NGM, but did not adjust
for potential confounders, such as age, mean BPs or the use
of various classes of antihypertensive medication [5,6].
Hence, the results of the current study, in a population-based
cohort enriched with individuals with T2DM, add to the
existing literature by presenting accurate (differences in)
BPV estimates, as we adhered to international guidelines
on BP measurements [15,16,18] and were able to adjust for a
large number of potential confounders.
The slightly greater very short-term to mid-term BPV in
individuals with (pre)diabetes may be related to several
factors, such as impaired baroreflex sensitivity caused by
arterial carotid stiffening [25–27], and overactivity of the
sympathetic nervous system caused by obesity [28] and/or
(undiagnosed) sleep disordered breathing [29–31]. Further
study is required to test these hypotheses.
Previous studies have suggested that in the presence of
T2DM, CVD risk increases more in women as compared with
men [32]. Our results, however, showed no clear pattern with
regard to greater in BPV in women with (pre)diabetes, and
these findings may represent the play of chance.
A major strength of the current report is the precise
measurement of BPV estimates. In addition, OGTT-based
classification of glucose metabolism status and the over-
sampling of individuals with T2DM enabled sufficient statis-
tical power to accurately estimate BPV in (pre)diabetes. Also,
we were able to adjust for an extensive range of covariates,
including the use of various classes of antihypertensive
medication. In fact, this may have led to some overadjust-
ment, as, for instance, decreased renal function may lie in the
causal pathway between (pre)diabetes and greater BPV.
Consequently,wemay, to someextent, haveunderestimated
differences in BPV between individuals with (pre)diabetes
and NGM [33]. Therefore, the true association will lie be-
tween model 3, in which only true confounders were added,
and model 4. Even so, however, model 3 still shows that
differences in BPV between individuals with (pre)diabetes
and NGM are relatively modest. On the other hand, it should
be emphasized that these modest differences were obtained
in a study population that was well treated with regard to BP.
Importantly, the latter implies that BPV-associated risk of
CVD in (pre)diabetes can be reduced to approximately the
same level as in individuals with NGM.
The current study had some further limitations. First, in
light of the above, the generalizability of our results may be
limited to white populations and those who had access to
high-quality hypertension care. Second, due to the cross-
sectional design of the study, any causal inference should be
madewith caution.Third, data on long-termBPV, that is visit-
to-visit BPV, were unavailable. Visit-to-visit BPV has been
strongly associated with incident CVD [34], and is a distinct
type of BPV, as its underlying mechanisms are different from
those of other types of BPV and include aging and seasonal
climatic changes [35]. Hence, long-term BPV is not inter-
changeable with (very) short-term BPV [4,36].
In conclusion, individuals with (pre)diabetes have a
slightly greater very short-term to mid-term BPV than those
with NGM, which may explain a small part of the increased
CVD risk seen in (pre)diabetes. Despite these small differ-
ences, very short-term to mid-term BPV remains substantial
and important in individuals with and without (pre)diabe-
tes. The results of the current study imply that greater very
short-term to mid-term BPV may need to be considered as
an important, treatable risk factor for CVD, regardless of
glucose metabolism status. In addition, these results may
also imply that when hypertension is well controlled, as is
the case in our study population, the BPV-associated risk on
CVD in (pre)diabetes may be reduced to approximately the
same level as in individuals with NGM. Future research
should explore whether the same applies to long-term BPV,
that is visit-to-visit BPV, in individuals with and without
(pre)diabetes.
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Reviewer’s Summary Evaluation
Reviewer 2
The study examined short-term and long-term measures of
BP variability in over 3000 normal patients and those with
prediabetes and diabetes. The strength of the analysis
employed is the multiple linear regression with adjustment
for potential confounders and included five different mod-
els. The main findings were that greater nocturnal systolic
blood pressure variability and greatest seven-day systolic
variability and diastolic variability in patients with diabetes
compared to normal subjects. By contrast, prediabetic’s
were associated with a greater within visit systolic blood
pressure variability only. It must be said that differences
between the three groups were relatively small and wheth-
er this is enough to predict increased cardiovascular risk
would need to be determined in the long-term.
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